WOCKPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 2.7
| Stock Code | WOCKPHARMA | Market Cap | 19,246 Cr. | Current Price | 1,187 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 95.8 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,333 ₹ | DMA 200 | 1,378 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 54.0 Cr. |
| RSI | 32.1 | MACD | -46.8 | Volume | 3,72,143 | Avg Vol 1Wk | 6,16,325 |
| Low price | 1,154 ₹ | High price | 1,870 ₹ | PEG Ratio | 3.96 | Debt to equity | 0.76 |
| 52w Index | 4.60 % | Qtr Profit Var | 273 % | EPS | 11.8 ₹ | Industry PE | 27.2 |
📊 Analysis: WOCKPHARMA shows weak fundamentals with ROCE at 4.40% and negative ROE (-0.53%), indicating poor efficiency and shareholder returns. The stock trades at a steep valuation with a P/E of 95.8 compared to the industry average of 27.2, and a PEG ratio of 3.96 suggests significant overvaluation relative to growth. Dividend yield is 0%, offering no income support. Debt-to-equity at 0.76 is relatively high, adding financial risk. Technical indicators (RSI 32.1, MACD -46.8) show bearish momentum, with the stock trading below both 50 DMA and 200 DMA. Quarterly PAT declined from ₹54 Cr. to ₹38 Cr., raising concerns about earnings consistency despite EPS of ₹11.8.
💰 Entry Price Zone: Ideal accumulation zone lies between ₹1,150 – ₹1,200, near its recent low of ₹1,154, offering a safer entry point given stretched valuations.
📈 Exit / Holding Strategy: If already holding, investors should adopt a cautious medium-term horizon (2–3 years). Exit strategy should be considered if profitability fails to recover, as ROE remains negative and debt levels are high. A trailing stop-loss near ₹1,120 can protect downside. Long-term investors may hold only if earnings stabilize and ROE turns positive.
✅ Positive
- EPS at ₹11.8 reflects a consistent earnings base despite volatility.
- Quarterly profit variation (+273%) shows some recovery momentum.
⚠️ Limitation
- High P/E (95.8) compared to industry average (27.2).
- Negative ROE (-0.53%) and weak ROCE (4.40%).
- PEG ratio (3.96) indicates overvaluation relative to growth.
- Dividend yield is 0%, limiting investor appeal.
- Debt-to-equity at 0.76 is relatively high.
📉 Company Negative News
- Quarterly PAT declined from ₹54 Cr. to ₹38 Cr.
- FII (-0.10%) and DII (-0.45%) holdings reduced, showing weaker institutional sentiment.
- Stock trading below DMA 50 (₹1,333) and DMA 200 (₹1,378).
- Bearish technical indicators (RSI below 35, MACD negative).
📈 Company Positive News
- EPS at ₹11.8 provides a base for potential recovery.
- Quarterly profit variation (+273%) indicates earnings rebound from prior weakness.
🏭 Industry
- Industry P/E at 27.2 reflects moderate sector valuations.
- WOCKPHARMA trades at a steep premium despite weak fundamentals.
🔎 Conclusion
WOCKPHARMA is a high-risk stock with weak profitability, high debt, and stretched valuations. Long-term investment is not advisable unless earnings stabilize and ROE turns positive. Investors should only accumulate near ₹1,150–₹1,200 for speculative exposure. Existing holders may continue with a medium-term horizon but should monitor profitability closely and exit if recovery fails to materialize.